合作类型：技术   行业类别: 生物科学与健康   国家：西班牙 

过期时间：2017年05月25日  

 一个包含三家西班牙研究机构的团体发现了一种治愈和阻止HIV/AIDS感染主体的方法，该方法需要使用一种无法复制的病毒或一个激活的免疫细胞。这种新的治疗方法有效安全且能阻止感染。该团体正在寻找生物科技或者制药公司进行后续发展的许可证协议合作。

英语原文：

Summary:

A group of three Spanish research organizations have discovered a method for the treatment or prevention of the infection caused by HIV and/or AIDS in a subject in the need thereof comprising the administration of non-replicative virions or an activated immune cell. It is an effective and safe treatment or prevention from the infection. They are looking for a biotech or pharmaceutical company for a licence agreement for further development.

Details:

AIDS is one of the infectious diseases which cause the most death worldwide and it is calculated that over 14.000 new infections take place every day. It has been impossible to eradicate the specific responses against HIV in HIV–infected people. There is a therapeutic arsenal of treatments against the infection of the virus, but there is a real lack of vaccines in this field.

Traditional vaccine strategies from attenuated viruses cannot be used to prevent HIV infection or therapeutically due to safety problems or because its inefficacy when used. There is no preventive or therapeutic vaccine discovered at least, due to among other reasons the genetic diversity of the virus, fast replication rate, high mutation frequency, difficulty for inducing neutralizing antibodies, etc. These are the reasons why is so needed an effective and safe HIV vaccine as described below.

They have found a viral vector comprising a human immunodeficiency virus (HIV) genome containing various mutations in several positions of this genome, wherein said mutations cause the virus produced solely from said viral vector to be a non-replicative virus. The non-replicative virions, comprising a viral vector, are produced by transfecting the cells with the viral vector. So when infecting an immune cell with the non-replicative virion, those cells process the antigens originating from the non-replicative virion and are capable of generating an immune response. On this way, as are obtained activated immune cells along with the non-replicative virions, it has been developed a customized vaccine against the HIV as therapeutic treatment preventing the HIV infection.

Type and Role of Partners Sought:

Pharmaceutical and biotech companies working in the field of virus vaccines or therapeutical developments, that should have to adapt and develop the technology for its commercialization.